ONCO
Onconetix, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.43
−10.13%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$0.48
From 52W high−99.77%
Volume361037.00
Market cap$2.26M
P/E (TTM)—
P/S (TTM)3.5x
Div yield—
Key dataOct 19, 2026
Open
$0.48
From 52W high
−99.77%
Volume
361037.00
Market cap
$2.26M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.4x
P/E (TTM)
—
RSI (14)
33.3
MomentumView details →
1D Return
−10.13%
YTD Return
−99.42%
SummaryUpdated Jun 1, 2026
Onconetix, Inc. (NASDAQ:ONCO) is a biotechnology and pharmaceutical company founded in 2018 and headquartered in Cincinnati, Ohio. Originally incorporated as Blue Water Biotech, Inc., the company changed its name to Onconetix in December 2023. The company went public in February 2022 and focuses on developing and commercializing transformational therapies to address various health challenges worldwide. Onconetix operates in the biotechnology sector with a dual focus on commercializing existing FDA-approved treatments and developing innovative vaccine candidates for infectious diseases.
Similar companies
Latest newsMore news →
SRX Global added a minority investment in Onconetix (Nasdaq: ONCO) ahead of the anticipated closing of the Realbotix LLC acquisition.26d agoOnconetix, Inc. agreed to lend Realbotix, LLC up to $5.0 million under an unsecured grid promissory note, with $2.5 million advanced initially, maturing September 11, 2027.36d agoRealbotix LLC, a wholly owned subsidiary of Realbotix Corp., entered into an unsecured bridge loan facility with Onconetix, Inc. in connection with their proposed merger.36d ago